Details

Autor(en) / Beteiligte

• Peterson, Alan L
• Blount, Tabatha H
• Foa, Edna B
• Brown, Lily A
• McLean, Carmen P
• Mintz, Jim
• Schobitz, Richard P
• DeBeer, Bryann R
• Mignogna, Joseph
• Fina, Brooke A
• Evans, Wyatt R
• Synett, Samantha
• Hall-Clark, Brittany N
• Rentz, Timothy O
• Schrader, Christian
• Yarvis, Jeffrey S
• Dondanville, Katherine A
• Hansen, Hunter
• Jacoby, Vanessa M
• Lara-Ruiz, Jose
• Straud, Casey L
• Hale, Willie J
• Shah, Dhiya
• Koch, Lauren M
• Gerwell, Kelsi M
• Young-McCaughan, Stacey
• Litz, Brett T
• Meyer, Eric C
• Blankenship, Abby E
• Williamson, Douglas E
• Roache, John D
• Javors, Martin A
• Sharrieff, Allah-Fard M
• Niles, Barbara L
• Keane, Terence M

Titel

Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial

Ist Teil von

• JAMA network open, 2023-01, Vol.6 (1), p.e2249422-e2249422

Ort / Verlag

United States: American Medical Association

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Improved, efficient, and acceptable treatments are needed for combat-related posttraumatic stress disorder (PTSD). To determine the efficacy of 2 compressed prolonged exposure (PE) therapy outpatient treatments for combat-related PTSD. This randomized clinical trial was conducted among military personnel and veterans at 4 sites in Texas from 2017 to 2019. Assessors were blinded to conditions. Data were analyzed from November 2020 to October 2022. The interventions were massed-PE, which included 15 therapy sessions of 90 minutes each over 3 weeks, vs intensive outpatient program PE (IOP-PE), which included 15 full-day therapy sessions over 3 weeks with 8 treatment augmentations. The IOP-PE intervention was hypothesized to be superior to massed-PE. Coprimary outcomes included the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5) (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5) administered at baseline and posttreatment follow-ups. Measures ranged from 0 to 80, with higher scores indicating greater severity. Diagnostic remission and reliable change were secondary outcomes. Among 319 military personnel and veterans screened, 234 were randomized (mean [SD] age, 39.20 [7.72] years; 182 [78%] male participants), with 117 participants randomized to IOP-PE and 117 participants randomized to massed-PE. A total of 61 participants (26%) were African American, 58 participants (25%) were Hispanic, and 102 participants (44%) were White; 151 participants (65%) were married. Linear mixed-effects models found that CAPS-5 scores decreased in both treatment groups at the 1-month follow-up (IOP-PE: mean difference, -13.85 [95% CI, -16.47 to -11.23]; P < .001; massed-PE: mean difference, -14.13 [95% CI, -16.63 to -11.62]; P < .001). CAPS-5 change scores differed from 1- to 6-month follow-ups (mean difference, 4.44 [95% CI, 0.89 to 8.01]; P = .02). PTSD symptoms increased in massed-PE participants during follow-up (mean difference, 3.21 [95% CI, 0.65 to 5.77]; P = .01), whereas IOP-PE participants maintained treatment gains (mean difference, 1.23 [95% CI, -3.72 to 1.27]; P = .33). PCL-5 scores decreased in both groups from baseline to 1-month follow-up (IOP-PE: mean difference, -21.81 [95% CI, -25.57 to -18.04]; P < .001; massed-PE: mean difference, -19.96 [95% CI, -23.56 to -16.35]; P < .001) and were maintained at 6 months (IOP-PE: mean change, -0.21 [95% CI, -3.47 to 3.06]; P = .90; massed-PE: mean change, 3.02 [95% CI, -0.36 to 6.40]; P = .08). Both groups had notable PTSD diagnostic remission at posttreatment (IOP-PE: 48% [95% CI, 36% to 61%] of participants; massed-PE: 62% [95% CI, 51% to 73%] of participants), which was maintained at 6 months (IOP-PE: 53% [95% CI, 40% to 66%] of participants; massed-PE: 52% [95% CI, 38% to 66%] of participants). Most participants demonstrated reliable change on the CAPS-5 (61% [95% CI, 52% to 69%] of participants) and the PCL-5 (74% [95% CI, 66% to 81%] of participants) at the 1-month follow-up. These findings suggest that PE can be adapted into compressed treatment formats that effectively reduce PTSD symptoms. ClinicalTrials.gov Identifier: NCT03529435.